252 related articles for article (PubMed ID: 15668979)
21. Duodenal levodopa infusion improves quality of life in advanced Parkinson's disease.
Antonini A; Mancini F; Canesi M; Zangaglia R; Isaias IU; Manfredi L; Pacchetti C; Zibetti M; Natuzzi F; Lopiano L; Nappi G; Pezzoli G
Neurodegener Dis; 2008; 5(3-4):244-6. PubMed ID: 18322402
[TBL] [Abstract][Full Text] [Related]
22. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal.
Slevin JT; Gash DM; Smith CD; Gerhardt GA; Kryscio R; Chebrolu H; Walton A; Wagner R; Young AB
Neurosurg Focus; 2006 May; 20(5):E1. PubMed ID: 16711657
[TBL] [Abstract][Full Text] [Related]
23. Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.
Stacy M; Bowron A; Guttman M; Hauser R; Hughes K; Larsen JP; LeWitt P; Oertel W; Quinn N; Sethi K; Stocchi F
Mov Disord; 2005 Jun; 20(6):726-33. PubMed ID: 15719426
[TBL] [Abstract][Full Text] [Related]
24. Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus.
Østergaard K; Aa Sunde N
Mov Disord; 2006 May; 21(5):624-31. PubMed ID: 16283616
[TBL] [Abstract][Full Text] [Related]
25. Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease.
Whone A; Luz M; Boca M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
Brain; 2019 Mar; 142(3):512-525. PubMed ID: 30808022
[TBL] [Abstract][Full Text] [Related]
26. Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
Alvarez L; Macias R; Lopez G; Alvarez E; Pavon N; Rodriguez-Oroz MC; Juncos JL; Maragoto C; Guridi J; Litvan I; Tolosa ES; Koller W; Vitek J; DeLong MR; Obeso JA
Brain; 2005 Mar; 128(Pt 3):570-83. PubMed ID: 15689366
[TBL] [Abstract][Full Text] [Related]
27. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up.
Rodriguez-Oroz MC; Obeso JA; Lang AE; Houeto JL; Pollak P; Rehncrona S; Kulisevsky J; Albanese A; Volkmann J; Hariz MI; Quinn NP; Speelman JD; Guridi J; Zamarbide I; Gironell A; Molet J; Pascual-Sedano B; Pidoux B; Bonnet AM; Agid Y; Xie J; Benabid AL; Lozano AM; Saint-Cyr J; Romito L; Contarino MF; Scerrati M; Fraix V; Van Blercom N
Brain; 2005 Oct; 128(Pt 10):2240-9. PubMed ID: 15975946
[TBL] [Abstract][Full Text] [Related]
28. Trophic factor distribution predicts functional recovery in parkinsonian monkeys.
Gash DM; Zhang Z; Ai Y; Grondin R; Coffey R; Gerhardt GA
Ann Neurol; 2005 Aug; 58(2):224-33. PubMed ID: 16049934
[TBL] [Abstract][Full Text] [Related]
29. Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease.
Siderowf A; Jaggi JL; Xie SX; Loveland-Jones C; Leng L; Hurtig H; Colcher A; Stern M; Chou KL; Liang G; Maccarone H; Simuni T; Baltuch G
Mov Disord; 2006 Jun; 21(6):746-53. PubMed ID: 16463342
[TBL] [Abstract][Full Text] [Related]
30. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease.
Kordower JH; Palfi S; Chen EY; Ma SY; Sendera T; Cochran EJ; Cochran EJ; Mufson EJ; Penn R; Goetz CG; Comella CD
Ann Neurol; 1999 Sep; 46(3):419-24. PubMed ID: 10482276
[TBL] [Abstract][Full Text] [Related]
31. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.
Honig H; Antonini A; Martinez-Martin P; Forgacs I; Faye GC; Fox T; Fox K; Mancini F; Canesi M; Odin P; Chaudhuri KR
Mov Disord; 2009 Jul; 24(10):1468-74. PubMed ID: 19425079
[TBL] [Abstract][Full Text] [Related]
32. The neuroprotective effect of glial cell line-derived neurotrophic factor in fibrin glue against chronic focal cerebral ischemia in conscious rats.
Cheng H; Huang SS; Lin SM; Lin MJ; Chu YC; Chih CL; Tsai MJ; Lin HC; Huang WC; Tsai SK
Brain Res; 2005 Feb; 1033(1):28-33. PubMed ID: 15680336
[TBL] [Abstract][Full Text] [Related]
33. Differential effects of growth/differentiation factor 5 and glial cell line-derived neurotrophic factor on dopaminergic neurons and astroglia in cultures of embryonic rat midbrain.
Wood TK; McDermott KW; Sullivan AM
J Neurosci Res; 2005 Jun; 80(6):759-66. PubMed ID: 15880784
[TBL] [Abstract][Full Text] [Related]
34. Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.
Andereggen L; Meyer M; Guzman R; Ducray AD; Widmer HR
Brain Res; 2009 Jun; 1276():39-49. PubMed ID: 19389387
[TBL] [Abstract][Full Text] [Related]
35. Neuroprotection for Parkinson's disease: prospects and promises.
Olanow CW; Schapira AH; Agid Y
Ann Neurol; 2003; 53 Suppl 3():S1-2. PubMed ID: 12666093
[No Abstract] [Full Text] [Related]
36. Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson's Disease.
Whone AL; Boca M; Luz M; Woolley M; Mooney L; Dharia S; Broadfoot J; Cronin D; Schroers C; Barua NU; Longpre L; Barclay CL; Boiko C; Johnson GA; Fibiger HC; Harrison R; Lewis O; Pritchard G; Howell M; Irving C; Johnson D; Kinch S; Marshall C; Lawrence AD; Blinder S; Sossi V; Stoessl AJ; Skinner P; Mohr E; Gill SS
J Parkinsons Dis; 2019; 9(2):301-313. PubMed ID: 30829619
[TBL] [Abstract][Full Text] [Related]
37. Localization of nerve growth factor, neurotrophin-3, and glial cell line-derived neurotrophic factor in nestin-expressing reactive astrocytes in the caudate-putamen of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated C57/Bl mice.
Chen LW; Zhang JP; Kwok-Yan Shum D; Chan YS
J Comp Neurol; 2006 Aug; 497(6):898-909. PubMed ID: 16802332
[TBL] [Abstract][Full Text] [Related]
38. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
39. Testosterone therapy in men with Parkinson disease: results of the TEST-PD Study.
Okun MS; Fernandez HH; Rodriguez RL; Romrell J; Suelter M; Munson S; Louis ED; Mulligan T; Foster PS; Shenal BV; Armaghani SJ; Jacobson C; Wu S; Crucian G
Arch Neurol; 2006 May; 63(5):729-35. PubMed ID: 16682542
[TBL] [Abstract][Full Text] [Related]
40. Long-term glial cell line-derived neurotrophic factor overexpression in the intact nigrostriatal system in rats leads to a decrease of dopamine and increase of tetrahydrobiopterin production.
Sajadi A; Bauer M; Thöny B; Aebischer P
J Neurochem; 2005 Jun; 93(6):1482-6. PubMed ID: 15935064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
